Hepatocytes: A key cell type for innate immunity

Cellular and Molecular Immunology

Volumn 13, Issue 3, 2016, Pages 301-315

  Zhou, Zhou ^a   Xu, Ming Jiang ^a   Gao, Bin ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CCAAT ENHANCER BINDING PROTEIN; CD14 ANTIGEN; COMPLEMENT FACTOR; CXCL1 CHEMOKINE; CYTOKINE; FIBRINOGEN; HEMOPEXIN; HEPATOCYTE NUCLEAR FACTOR; HEPCIDIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 6; LIPOPOLYSACCHARIDE BINDING PROTEIN; MANNOSE BINDING LECTIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OPSONIN; PROTEIN MD 2; PROTEINASE INHIBITOR; SERUM AMYLOID A; SERUM AMYLOID P; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL INFECTION; CELLS BY BODY ANATOMY; CHRONIC LIVER DISEASE; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DOWNSTREAM PROCESSING; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; IRON METABOLISM; LIVER CELL; LIVER CIRRHOSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM;

ANIMALS; CYTOKINES; HEPATOCYTES; HUMANS; IMMUNITY, INNATE; IMMUNOMODULATION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84966431031     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2015.97     Document Type: Review

References (174)

1. Gao B, Jeong WI, Tian Z. Liver: an organ with predominant innate immunity. Hepatology 2008; 47: 729-736.
2. Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol 2012; 33: 571-577.
3. Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 2014; 10: 720-727.
4. Norris CA, He M, Kang LI, Ding MQ, Radder JE, Haynes MM et al. Synthesis of IL-6 by hepatocytes is a normal response to common hepatic stimuli. PLoS One 2014; 9: e96053.
5. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-550.
6. Eder C. Mechanisms of interleukin-1beta release. Immunobiology 2009; 214: 543-553.
7. Bode JG, Albrecht U, Haussinger D, Heinrich PC, Schaper F. Hepatic acute phase proteins-regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-kappaB-dependent signaling. Eu J Cell Biol 2012; 91: 496-505.
8. Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol 2014; 32: 433-459.
9. Sarma JV, Ward PA. The complement system. Cell Tissue Res 2011; 343: 227-235.
10. Qin X, Gao B. The complement system in liver diseases. Cell Mol Immunol 2006; 3: 333-340.
11. Alper CA, Johnson AM, Birtch AG, Moore FD. Human C3: evidence for the liver as the primary site of synthesis. Science 1969; 163: 286-288.
12. Volanakis JE. Transcriptional regulation of complement genes. Annu Rev Immunol 1995; 13: 277-305.
13. Morgan BP, Gasque P. Extrahepatic complement biosynthesis: where, when and why? Clin Exp Immunol 1997; 107: 1-7.
14. Morris KM, Aden DP, Knowles BB, Colten HR. Complement biosynthesis by the human hepatoma-derived cell line HepG2. J Clin Invest 1982; 70: 906-913.
15. Alper CA, Johnson AM, Birtch AG, Moore FD. Human C3: evidence for the liver as the primary site of synthesis. Science 1969; 163: 286-288.
16. Bouwman LH, Roos A, Terpstra OT, de Knijff P, van Hoek B, Verspaget HW et al. Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterology 2005; 129: 408-414.
17. Schwaeble W, Dahl MR, Thiel S, Stover C, Jensenius JC. The mannan-binding lectin-associated serine proteases (MASPs) and MAp19: four components of the lectin pathway activation complex encoded by two genes. Immunobiology 2002; 205: 455-466.
18. Stover CM, Lynch NJ, Hanson SJ, Windbichler M, Gregory SG, Schwaeble WJ. Organization of the MASP2 locus and its expression profile in mouse and rat. Mamm Genome 2004; 15: 887-900.
19. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812.
20. Mortensen RF. C-reactive protein, inflammation, and innate immunity. Immunol Res 2001; 24: 163-176.
21. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004; 279: 48487-48490.
22. Inatsu A, Kinoshita M, Nakashima H, Shimizu J, Saitoh D, Tamai S et al. Novel mechanism of C-reactive protein for enhancing mouse liver innate immunity. Hepatology 2009; 49: 2044-2054.
23. Michelena J, Altamirano J, Abraldes JG, Affo S, Morales-Ibanez O, Sancho-Bru P et al. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology 2015; 62: 762-772.
24. Eklund KK, Niemi K, Kovanen PT. Immune functions of serum amyloid A. Crit Rev Immunol 2012; 32: 335-348.
25. Jensen LE, Whitehead AS. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 1998; 334: 489-503.
26. Shah C, Hari-Dass R, Raynes JG. Serum amyloid A is an innate immune opsonin for Gram-negative bacteria. Blood 2006; 108: 1751-1757.
27. Sander LE, Sackett SD, Dierssen U, Beraza N, Linke RP, MullerM et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med 2010; 207: 1453-1464.
28. Lee HY, Kim MK, Park KS, Shin EH, Jo SH, Kim SD et al. Serum amyloid A induces contrary immune responses via formyl peptide receptor-like 1 in human monocytes. Mol Pharmacol 2006; 70: 241-248.
29. He R, Sang H, Ye RD. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 2003; 101: 1572-1581.
30. He RL, Zhou J, Hanson CZ, Chen J, Cheng N, Ye RD. Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 2009; 113: 429-437.
31. Ather JL, Ckless K, Martin R, Foley KL, Suratt BT, Boyson JE et al. Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J Immunol 2011; 187: 64-73.
32. Lee HY, Kim SD, Shim JW, Lee SY, Lee H, Cho KH et al. Serum amyloid A induces CCL2 production via formyl peptide receptorlike 1-mediated signaling in human monocytes. J Immunol 2008; 181: 4332-4339.
33. Sandri S, Hatanaka E, Franco AG, Pedrosa AM, Monteiro HP, Campa A. Serum amyloid A induces CCL20 secretion in mononuclear cells through MAPK (p38 and ERK1/2) signaling pathways. Immunol Lett 2008; 121: 22-26.
34. Yuste J, Botto M, Bottoms SE, Brown JS. Serum amyloid P aids complement-mediated immunity to Streptococcus pneumoniae. PLoS Pathog 2007; 3: 1208-1219.
35. Ochrietor JD, Harrison KA, Zahedi K, Mortensen RF. Role of STAT3 and C/EBP in cytokine-dependent expression of the mouse serum amyloid P-component (SAP) and C-reactive protein (CRP) genes. Cytokine 2000; 12: 888-899.
36. Ma YJ, Doni A, Skjoedt MO, Honore C, Arendrup M, Mantovani A et al. Heterocomplexes of mannose-binding lectin and the pentraxins PTX3 or serum amyloid P component trigger cross-activation of the complement system. J Biol Chem 2011; 286: 3405-3417.
37. Mold C, Gresham HD, Du Clos TW. Serum amyloid P component and C-reactive protein mediate phagocytosis through murine Fc gamma Rs. J Immunol 2001; 166: 1200-1205.
38. Bharadwaj D, Mold C, Markham E, Du Clos TW. Serum amyloid P component binds to Fc gamma receptors and opsonizes particles for phagocytosis. J Immunol 2001; 166: 6735-6741.
39. Mold C, Baca R, Du Clos TW. Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcgamma receptors. J Autoimmun 2002; 19: 147-154.
40. Bijl M, Horst G, Bijzet J, Bootsma H, Limburg PC, Kallenberg CG. Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages. Arthritis Rheum 2003; 48: 248-254.
41. Bickerstaff MC, Botto M, Hutchinson WL, Herbert J, Tennent GA, Bybee A et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999; 5: 694-697.
42. Kaur S, Singh PP. Serum amyloid P-component-mediated inhibition of the uptake of Mycobacterium tuberculosis by macrophages, in vitro. Scand J Immunol 2004; 59: 425-431.
43. Singh PP, Kaur S. Serum amyloid P-component in murine tuberculosis: induction kinetics and intramacrophage Myco bacterium tuberculosis growth inhibition in vitro. Microbes Infect/ Institut Pasteur 2006; 8: 541-551.
44. de Haas CJ, van Leeuwen EM, van Bommel T, Verhoef J, van Kessel KP, van Strijp JA. Serum amyloid P component bound to gramnegative bacteria prevents lipopolysaccharide-mediated classical pathway complement activation. Infect Immun 2000; 68: 1753-1759.
45. Noursadeghi M, Bickerstaff MC, Gallimore JR, Herbert J, Cohen J, Pepys MB. Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc Natl Acad Sci U S A 2000; 97: 14584-14589.
46. Cox N, Pilling D, Gomer RH. Distinct Fcgamma receptors mediate the effect of serum amyloid p on neutrophil adhesion and fibrocyte differentiation. J Immunol 2014;193: 1701-1708.
47. Murray LA, Chen Q, Kramer MS, Hesson DP, Argentieri RL, Peng X et al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int J Biochem Cell Biol 2011; 43: 154-162.
48. Murray LA, Rosada R, Moreira AP, Joshi A, Kramer MS, Hesson DP et al. Serum amyloid P therapeutically attenuates murine bleomycininduced pulmonary fibrosis via its effects on macrophages. PLoS One 2010; 5: e9683.
49. Zhang W, Xu W, Xiong S. Macrophage differentiation and polarization via phosphatidylinositol 3-kinase/Akt-ERK signaling pathway conferred by serum amyloid P component. J Immunol 2011; 187: 1764-1777.
50. Castano AP, Lin SL, Surowy T, Nowlin BT, Turlapati SA, Patel T et al. Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Transl Med 2009; 1: 5ra13.
51. Kirschning CJ, Unbehaun A, Fiedler G, Hallatschek W, Lamping N, Pfeil D et al. The transcriptional activation pattern of lipopoly saccharide binding protein (LBP) involving transcription factors AP-1 and C/EBP beta. Immunobiology 1997; 198: 124-135.
52. Wolk K, Witte E, Hoffmann U, Doecke WD, Endesfelder S, Asadullah K et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohns disease. J Immunol 2007; 178: 5973-5981.
53. Kirschning C, Unbehaun A, Lamping N, Pfeil D, Herrmann F, Schumann RR. Control of transcriptional activation of the lipopolysaccharide binding protein (LBP) gene by proinflammatory cytokines. Cytokines Cell Mol Ther 1997; 3: 59-62.
54. Su GL, Dorko K, Strom SC, Nussler AK, Wang SC. CD14 expression and production by human hepatocytes. J Hepatol 1999; 31: 435-442.
55. Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C. CD14 is an acute-phase protein. J Immunol 2004; 172: 4470-4479.
56. Pan Z, Zhou L, Hetherington CJ, Zhang DE. Hepatocytes contribute to soluble CD14 production, and CD14 expression is differentially regulated in hepatocytes and monocytes. J Biol Chem 2000; 275: 36430-36435.
57. Liu S, Shapiro RA, Nie S, Zhu D, Vodovotz Y, Billiar TR. Characterization of rat CD14 promoter and its regulation by tran scription factors AP1 and Sp family proteins in hepatocytes. Gene 2000; 250: 137-147.
58. Tissieres P, Dunn-Siegrist I, Schappi M, Elson G, Comte R, Nobre V et al. Soluble MD-2 is an acute-phase protein and an opsonin for Gram-negative bacteria. Blood 2008; 111: 2122-2131.
59. Tissieres P, Araud T, Ochoda A, Drifte G, Dunn-Siegrist I, Pugin J. Cooperation between PU. 1 and CAAT/enhancer-binding protein beta is necessary to induce the expression of the MD-2 gene. J Biol Chem 2009; 284: 26261-26272.
60. Schumann RR, Kirschning CJ, Unbehaun A, Aberle HP, Knope HP, Lamping N et al. The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is tran scriptionally activated by APRF/STAT/3 and other cytokineinducible nuclear proteins. Mol Cell Biol 1996; 16: 3490-3503.
61. Weiss J. Bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP): structure, function and regulation in host defence against Gram-negative bacteria. Biochem Soc Trans 2003; 31: 785-790.
62. Fan MH, Klein RD, Steinstraesser L, Merry AC, Nemzek JA, Remick DG et al. An essential role for lipopolysaccharide-binding protein in pulmonary innate immune responses. Shock 2002; 18: 248-254.
63. Jack RS, Fan X, Bernheiden M, Rune G, Ehlers M, Weber A et al. Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection. Nature 1997; 389: 742-745.
64. Yang KK, Dorner BG, Merkel U, Ryffel B, Schutt C, GolenbockD et al. Neutrophil influx in response to a peritoneal infection with Salmonella is delayed in lipopolysaccharide-binding protein or CD14-deficient mice. J Immunol 2002; 169: 4475-4480.
65. Knapp S, de Vos AF, Florquin S, Golenbock DT, van der Poll T. Lipopolysaccharide binding protein is an essential component of the innate immune response to Escherichia coli peritonitis in mice. Infect Immun 2003; 71: 6747-6753.
66. Le Roy D, Di Padova F, Tees R, Lengacher S, Landmann R, Glauser MP et al. Monoclonal antibodies to murine lipopolysaccharide (LPS)-binding protein (LBP) protect mice from lethal endotoxemia by blocking either the binding of LPS to LBP or the presentation of LPS/LBP complexes to CD14. J Immunol 1999; 162: 7454-7460.
67. Schumann RR. Old and new findings on lipopolysaccharide-binding protein: a soluble pattern-recognition molecule. Biochem Soc Trans 2011; 39: 989-993.
68. Vreugdenhil AC, Rousseau CH, Hartung T, Greve JW, van t Veer C, Buurman WA. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol 2003; 170: 1399-1405.
69. Weber JR, Freyer D, Alexander C, Schroder NW, Reiss A, Kuster C et al. Recognition of pneumococcal peptidoglycan: an expanded, pivotal role for LPS binding protein. Immunity 2003; 19: 269-279.
70. Schroder NW, Heine H, Alexander C, Manukyan M, Eckert J, Hamann L et al. Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses. J Immunol 2004; 173: 2683-2691.
71. Schroder NW, Morath S, Alexander C, Hamann L, Hartung T, Zahringer U et al. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 2003; 278: 15587-15594.
72. Branger J, Florquin S, Knapp S, Leemans JC, Pater JM, Speelman P et al. LPS-binding protein-deficient mice have an impaired defense against Gram-negative but not Gram-positive pneumonia. Int Immunol 2004; 16: 1605-1611.
73. Mueller M, Stamme C, Draing C, Hartung T, Seydel U, Schromm AB. Cell activation of human macrophages by lipoteichoic acid is strongly attenuated by lipopolysaccharide-binding protein. J Biol Chem 2006; 281: 31448-31456.
74. Hermann C, Spreitzer I, Schroder NW, Morath S, Lehner MD, Fischer W et al. Cytokine induction by purified lipoteichoic acids from various bacterial species-role of LBP, sCD14, CD14 and failure to induce IL-12 and subsequent IFN-gamma release. Eur J Immunol 2002: 32: 541-551.
75. Damien P, Cognasse F, Eyraud MA, Arthaud CA, Pozzetto B, Garraud O et al. LPS stimulation of purified human platelets is partly dependent on plasma soluble CD14 to secrete their main secreted product, soluble-CD40-Ligand. BMC Immunol 2015; 16: 3.
76. Moreno C, Merino J, Ramirez N, Echeverria A, Pastor F, Sanchez- Ibarrola A. Lipopolysaccharide needs soluble CD14 to interact with TLR4 in human monocytes depleted of membrane CD14. Microb Infect/Institut Pasteur 2004; 6: 990-995.
77. Asai Y, Makimura Y, Kawabata A, Ogawa T. Soluble CD14 discriminates slight structural differences between lipid as that lead to distinct host cell activation. J Immunol 2007; 179: 7674-7683.
78. Ohnishi T, Muroi M, Tanamoto K. Inhibitory effects of soluble MD-2 and soluble CD14 on bacterial growth. Microbiol Immunol 2010; 54: 74-80.
79. Kitchens RL, Thompson PA, Viriyakosol S, OKeefe GE, Munford RS. Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 2001; 108: 485-493.
80. Jacque B, Stephan K, Smirnova I, Kim B, Gilling D, Poltorak A. Mice expressing high levels of soluble CD14 retain LPS in the circulation and are resistant to LPS-induced lethality. Eur J Immunol 2006; 36: 3007-3016.
81. Ranoa DR, Kelley SL, Tapping RI. Human lipopolysaccharidebinding protein (LBP) and CD14 independently deliver triacylated lipoproteins to toll-like receptor 1 (TLR1) and TLR2 and enhance formation of the ternary signaling complex. J Biol Chem 2013; 288: 9729-9741.
82. Puertollano MA, Puertollano E, de Cienfuegos GA, de Pablo MA. Dietary antioxidants: immunity and host defense. Current Topics Med Chem 2011; 11: 1752-1766.
83. Wintergerst ES, Maggini S, Hornig DH. Contribution of selected vitamins and trace elements to immune function. Ann Nutr Metab 2007; 51: 301-323.
84. Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science 2012;338: 768-772.
85. Gomme PT, McCann KB, Bertolini J. Transferrin: structure, function and potential therapeutic actions. Drug Discov Today 2005; 10: 267-273.
86. Zakin MM. Regulation of transferrin gene expression. FASEB J 1992; 6: 3253-3258.
87. Aisen P, Leibman A, Zweier J. Stoichiometric and site char acteristics of the binding of iron to human transferrin. J Biol Chem 1978; 253: 1930-1937.
88. Eckenroth BE, Steere AN, Chasteen ND, Everse SJ, Mason AB. How the binding of human transferrin primes the transferrin receptor potentiating iron release at endosomal pH. Proc Natl Acad Sci USA 2011; 108: 13089-13094.
89. Andres MT, Fierro JF. Antimicrobial mechanism of action of transferrins: selective inhibition of H1-ATPase. Antimicrob Agents Chemother 2010; 54: 4335-4342.
90. Lin L, Pantapalangkoor P, Tan B, Bruhn KW, Ho T, Nielsen T et al. Transferrin iron starvation therapy for lethal bacterial and fungal infections. J Infect Dis 2014; 10: 254-264.
91. Rooijakkers SH, Rasmussen SL, McGillivray SM, Bartnikas TB, Mason AB, Friedlander AM et al. Human transferrin confers serum resistance against Bacillus anthracis. J Biol Chem 2010; 285: 27609-27613.
92. von Bonsdorff L, Sahlstedt L, Ebeling F, Ruutu T, Parkkinen J. Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron. FEMS Immunol Med Microbiol 2003; 37: 45-51.
93. Barber MF, Elde NC. Nutritional immunity. Escape from bacterial iron piracy through rapid evolution of transferrin. Science 2014, 346: 1362-1366.
94. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004; 432: 917-921.
95. Wu H, Santoni-Rugiu E, Ralfkiaer E, Porse BT, Moser C, Hoiby N et al. Lipocalin 2 is protective against E. coli pneumonia. Respir Res 2010; 11: 96.
96. Bachman MA, Oyler JE, Burns SH, Caza M, Lepine F, Dozois CM et al. Klebsiella pneumoniae yersiniabactin promotes respiratory tract infection through evasion of lipocalin 2. Infect Immun 2011; 79: 3309-3316.
97. Xu MJ, Feng D, WuH, Wang H, Chan Y, Kolls J et al. Liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: a critical role for IL-6/STAT3. Hepatology 2015; 61: 692-702.
98. Bachman MA, Lenio S, Schmidt L, Oyler JE, Weiser JN. Interaction of lipocalin 2, transferrin, and siderophores determines the replicative niche of Klebsiella pneumoniae during pneumonia. mBio 2012; 3: pii: e00224-11.
99. Guglani L, Gopal R, Rangel-Moreno J, Junecko BF, Lin Y, Berger T et al. Lipocalin 2 regulates inflammation during pulmonary mycobacterial infections. PLoS One 2012; 7: e50052.
100. Sickinger S, Maier H, Konig S, Vallant N, Kofler M, Schumpp P et al. Lipocalin-2 as mediator of chemokine expression and granulocyte infiltration during ischemia and reperfusion. Transpl Int 2013; 26: 761-769.
101. Guo H, Jin D, Chen X. Lipocalin 2 is a regulator of macrophage polarization and NF-kappaB/STAT3 pathway activation. Mol Endocrinol 2014; 28: 1616-1628.
102. Cheng L, Xing H, Mao X, Li L, Li X, Li Q. Lipocalin-2 promotes m1 macrophages polarization in a mouse cardiac ischaemia-reperfusion injury model. Scand J Immunol 2015; 81: 31-38.
103. Rocha ER, Smith A, Smith CJ, Brock JH. Growth inhibition of Bacteroides fragilis by hemopexin: proteolytic degradation of hemopexin to overcome heme limitation. FEMS Microbiol Lett 2001; 199: 73-78.
104. Larsen R, Gozzelino R, Jeney V, Tokaji L, Bozza FA, Japiassu AM et al. A central role for free heme in the pathogenesis of severe sepsis. Sci Trans Med 2010; 2: 51ra71.
105. Liang X, Lin T, Sun G, Beasley-Topliffe L, Cavaillon JM, Warren HS. Hemopexin down-regulates LPS-induced proinflammatory cytokines from macrophages. J Leukocyte Biol 2009; 86: 229-235.
106. Lin T, Sammy F, Yang H, Thundivalappil S, Hellman J, Tracey KJ et al. Identification of hemopexin as an anti-inflammatory factor that inhibits synergy of hemoglobin withHMGB1in sterile and infectious inflammation. J Immunol 2012; 189: 2017-2022.
107. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810.
108. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz- Knappe P et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000; 480: 147-150.
109. Ganz T. Hepcidin in iron metabolism. Curr Opin Hematol 2004; 11: 251-254.
110. Singh B, Arora S, Agrawal P, Gupta SK. Hepcidin: a novel peptide hormone regulating iron metabolism. Clin Chim Acta 2011; 412: 823-830.
111. Fish RJ, Neerman-Arbez M. Fibrinogen gene regulation. Thromb Haemost 2012; 108: 419-426.
112. Pahlman LI, Morgelin M, Kasetty G, Olin AI, Schmidtchen A, Herwald H. Antimicrobial activity of fibrinogen and fibrinogenderived peptides-a novel link between coagulation and innate immunity. Thromb Haemost 2013; 109: 930-939.
113. Endo Y, Nakazawa N, Iwaki D, Takahashi M, Matsushita M, Fujita T. Interactions of ficolin and mannose-binding lectin with fibrinogen/ fibrin augment the lectin complement pathway. J Innate Immun 2010; 2: 33-42.
114. Hoppe B. Fibrinogen and factor XIII at the intersection of coagulation, fibrinolysis and inflammation. Thromb Haemost 2014; 112: 649-658.
115. Pluskota E, Soloviev DA, Szpak D, Weber C, Plow EF. Neutrophil apoptosis: selective regulation by different ligands of integrin alphaMbeta2. J Immunol 2008; 181: 3609-3619.
116. Solovjov DA, Pluskota E, Plow EF. Distinct roles for the alpha and beta subunits in the functions of integrin alphaMbeta2. J Biol Chem 2005; 280: 1336-1345.
117. Lishko VK, Kudryk B, Yakubenko VP, Yee VC, Ugarova TP. Regulated unmasking of the cryptic binding site for integrin alpha M beta 2 in the gamma C-domain of fibrinogen. Biochemistry 2002; 41: 12942-12951.
118. Orchekowski RP, Plescia J, Altieri DC, Bajt ML. AlphaMbeta2 (CD11b/CD18, Mac-1) integrin activation by a unique monoclonal antibody to alphaM I domain that is divalent cation-sensitive. J Leukocyte Biol 2000; 68: 641-649.
119. Flick MJ, Du X, Witte DP, Jirouskova M, Soloviev DA, Busuttil SJ et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest 2004; 113: 1596-1606.
120. Yan SR, Sapru K, Issekutz AC. The CD11/CD18 (beta2) integrins modulate neutrophil caspase activation and survival following TNFalpha or endotoxin induced transendothelial migration. Immunol Cell Biol 2004; 82: 435-446.
121. Rubel C, Gomez S, Fernandez GC, Isturiz MA, Caamano J, Palermo MS. Fibrinogen-CD11b/CD18 interaction activates the NF-kappa B pathway and delays apoptosis in human neutrophils. Eur J Immunol 2003; 33: 1429-1438.
122. Rubel C, Fernandez GC, Rosa FA, Gomez S, Bompadre MB, Coso OA et al. Soluble fibrinogen modulates neutrophil functionality through the activation of an extracellular signal-regulated kinase-dependent pathway. J Immunol 2002; 168: 3527-3535.
123. Flick MJ, Du X, Degen JL. Fibrin(ogen)-alpha M beta 2 interactions regulate leukocyte function and innate immunity in vivo. Exp Biol Med (Maywood) 2004; 229: 1105-1110.
124. Andus T, Gross V, Tran-Thi TA, Schreiber G, Nagashima M, Heinrich PC. The biosynthesis of acute-phase proteins in primary cultures of rat hepatocytes. Eur J Biochem 1983; 133: 561-571.
125. Armstrong PB, Quigley JP. Alpha2-macroglobulin: an evolutionarily conserved arm of the innate immune system. Dev Comp Immunol 1999; 23: 375-390.
126. Armstrong PB. Proteases and protease inhibitors: a balance of activities in host-pathogen interaction. Immunobiology 2006; 211: 263-281.
127. Hoijer MA, Melief MJ, Keck W, Hazenberg MP. Purification and characterization of N-acetylmuramyl-L-alanine amidase from human plasma using monoclonal antibodies. Biochim Biophy Acta 1996; 1289: 57-64.
128. Wang Z, Burke PA. Hepatocyte nuclear factor-4alpha interacts with other hepatocyte nuclear factors in regulating transthyretin gene expression. FEBS J 2010; 277: 4066-4075.
129. Shavva VS, Mogilenko DA, Dizhe EB, Oleinikova GN, Perevozchikov AP, Orlov SV. Hepatic nuclear factor 4alpha positively regulates complement C3 expression and does not interfere with TNFalphamediated stimulation of C3 expression in HepG2 cells. Gene 2013; 524: 187-192.
130. Schrem H, Klempnauer J, Borlak J. Liver-enriched transcription factors in liver function and development. Part II: the C/EBPs and D site-binding protein in cell cycle control, carcinogenesis, circadian gene regulation, liver regeneration, apoptosis, and liverspecific gene regulation. Pharmacol Rev 2004; 56: 291-330.
131. Juan TS, Wilson DR, Wilde MD, Darlington GJ. Participation of the transcription factor C/EBP delta in the acute-phase regulation of the human gene for complement component C3. Proc Natl Acad Sci USA 1993; 90: 2584-2588.
132. Gonzalez S, Lopez-Larrea C. Characterization of the human C6 promoter: requirement of the CCAAT enhancer binding protein binding site for C6 gene promoter activity. J Immunol 1996; 157: 2282-2290.
133. Gonzalez S, Martinez-Borra J, Lopez-Larrea C. Cloning and characterization of human complement component C7 promoter. Genes Immun 2003; 4: 54-59.
134. Huang JH, Liao WS. Induction of the mouse serum amyloid A3 gene by cytokines requires both C/EBP family proteins and a novel constitutive nuclear factor. Mol Cell Biol 1994; 14: 4475-4484.
135. Dalmon J, LaurentM, Courtois G. The human beta fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6- responsive element. Mol Cell Biol 1993; 13: 1183-1193.
136. Burgess-Beusse BL, Darlington GJ. C/EBPalpha is critical for the neonatal acute-phase response to inflammation. Mol Cell Biol 1998; 18: 7269-7277.
137. Singh PP, Voleti B, Agrawal A. A novel RBP-J kappa-dependent switch from C/EBP beta to C/EBP zeta at the C/EBP binding site on the C-reactive protein promoter. J Immunol 2007; 178: 7302-7309.
138. Welm AL, Mackey SL, Timchenko LT, Darlington GJ, Timchenko NA. Translational induction of liver-enriched transcriptional inhibitory protein during acute phase response leads to repression of CCAAT/ enhancer binding protein alpha mRNA. J Biol Chem 2000; 275: 27406-27413.
139. Cantwell CA, Sterneck E, Johnson PF. Interleukin-6-specific activation of the C/EBPdelta gene in hepatocytes is mediated by Stat3 and Sp1. Mol Cell Biol 1998; 18: 2108-2117.
140. Alam T, An MR, Papaconstantinou J. Differential expression of three C/EBP isoforms in multiple tissues during the acute phase response. J Biol Chem 1992; 267: 5021-5024.
141. Verschuur M, de Jong M, Felida L, de Maat MP, Vos HL. A hepatocyte nuclear factor-3 site in the fibrinogen beta promoter is important for interleukin 6-induced expression, and its activity is influenced by the adjacent -148C/T polymorphism. J Biol Chem 2005; 280: 16763-16771.
142. Patel DN, King CA, Bailey SR, Holt JW, Venkatachalam K, Agrawal A et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2- dependent NF-kappaB and C/EBPbeta activation. J Biol Chem 2007; 282: 27229-27238.
143. Ray A, Ray BK. Serum amyloid A gene expression under acute-phase conditions involves participation of inducible C/EBP-beta and C/EBP-delta and their activation by phosphorylation. Mol Cel Biol 1994; 14: 4324-4332.
144. Liang SC, Nickerson-Nutter C, Pittman DD, Carrier Y, Goodwin DG, Shields KM et al. IL-22 induces an acute-phase response. J Immunol 2010; 185: 5531-5538.
145. Park O, Wang H, Weng H, Feigenbaum L, Li H, Yin S et al. In vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression. Hepatology 2011; 54: 252-261.
146. Alonzi T, Maritano D, Gorgoni B, Rizzuto G, Libert C, Poli V. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. Mol Cell Biol 2001; 21: 1621-1632.
147. Nishikawa T, Hagihara K, Serada S, Isobe T, Matsumura A, Song J et al. Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol 2008; 180: 3492-3501.
148. Hagihara K, Nishikawa T, Sugamata Y, Song J, Isobe T, Taga T et al. Essential role of STAT3 in cytokine-drivenNF-kappaB-mediated serum amyloid A gene expression. Genes Cells 2005; 10: 1051-1063.
149. Poli V, Mancini FP, Cortese R. IL-6DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBP. Cell 1990;. 63: 643-653.
150. Yamada T, Tobita K, Osada S, Nishihara T, Imagawa M. CCAAT/ enhancer-binding protein delta gene expression is mediated by APRF/STAT3. J Biochem 1997; 121: 731-738.
151. Mogilenko DA, Kudriavtsev IV, Shavva VS, Dizhe EB, Vilenskaya EG, Efremov AM et al. Peroxisome proliferator-activated receptor alpha positively regulates complement C3 expression but inhibits tumor necrosis factor alpha-mediated activation of C3 gene in mammalian hepatic-derived cells. J Biol Chem 2013; 288: 1726-1738.
152. Kramer F, Torzewski J, Kamenz J, Veit K, Hombach V, Dedio J et al. Interleukin-1beta stimulates acute phase response and C-reactive protein synthesis by inducing an NFkappaB- and C/EBPbetadependent autocrine interleukin-6 loop. Mol Immunol 2008; 45: 2678-2689.
153. Yoshida Y, Kumar A, Koyama Y, Peng H, Arman A, Boch JA et al. Interleukin 1 activates STAT3/nuclear factor-kappaB cross-talk via a unique TRAF6- and p65-dependent mechanism. J Biol Chem 2004; 279: 1768-1776.
154. Agrawal A, Cha-Molstad H, Samols D, Kushner I. Transactivation of C-reactive protein by IL-6 requires synergistic interaction of CCAAT/ enhancer binding protein beta (C/EBP beta) and Rel p50. J Immunol 2001; 166: 2378-2384.
155. Quinton LJ, Blahna MT, Jones MR, Allen E, Ferrari JD, Hilliard KL et al. Hepatocyte-specific mutation of both NF-kappaB RelA and STAT3 abrogates the acute phase response in mice. J Clin Invest 2012; 122: 1758-1763.
156. Mandrekar P, Ambade A, Lim A, Szabo G, Catalano D. An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. Hepatology 2011; 54: 2185-2197.
157. Obstfeld AE, Sugaru E, Thearle M, Francisco AM, Gayet C, Ginsberg HN et al. C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes 2010; 59: 916-925.
158. Chang B, Xu MJ, Zhou Z, Cai Y, Li M, Wang W et al. Short- or longterm high-fat diet feeding plus acute ethanol binge synergistically induce acute liver injury in mice: an important role for CXCL1. Hepatology 2015; 62: 1070-1085.
159. Batra S, Cai S, Balamayooran G, Jeyaseelan S. Intrapulmonary administration of leukotriene B(4) augments neutrophil accumulation and responses in the lung to Klebsiella infection in CXCL1 knockout mice. J Immunol 2012; 188: 3458-3468.
160. Dziarski R, Gupta D. Review: mammalian peptidoglycan recognition proteins (PGRPs) in innate immunity. Innate Immun 2010; 16: 168-174.
161. Boneca IG. Mammalian PGRPs in the spotlight. Cell Host Microbe 2009; 5: 109-111.
162. Deng M, Scott MJ, Loughran P, Gibson G, Sodhi C, Watkins S et al. Lipopolysaccharide clearance, bacterial clearance, and systemic inflammatory responses are regulated by cell type-specific functions of TLR4 during sepsis. J Immunol 2013; 190: 5152-5160.
163. Herkel J, Jagemann B, Wiegard C, Lazaro JF, Lueth S, Kanzler S et al. MHC class II-expressing hepatocytes function as antigenpresenting cells and activate specific CD4 T lymphocyutes. Hepatology 2003; 37: 1079-1085.
164. Bertolino P, Trescol-Biemont MC, Rabourdin-Combe C. Hepatocytes induce functional activation of naive CD81 T lymphocytes but fail to promote survival. Eur J Immunol 1998; 28: 221-236.
165. Crispe IN. Hepatic T cells and liver tolerance. Nat Rev Immunol 2003; 3: 51-62.
166. Muhlbauer M, Fleck M, Schutz C, Weiss T, Froh M, Blank C et al. PDL1 is induced in hepatocytes by viral infection and by interferonalpha and -gamma and mediates T cell apoptosis. J Hepatol 2006; 45: 520-528.
167. Le Moine O, Deviere J, Devaster JM, Crusiaux A, Durand F, Bernuau J et al. Interleukin-6: an early marker of bacterial infection in decompensated cirrhosis. J Hepatol 1994; 20: 819-824.
168. Mackenzie I, Woodhouse J. C-reactive protein concentrations during bacteraemia: a comparison between patients with and without liver dysfunction. Intensive Care Med 2006; 32: 1344-1351.
169. Park WB, Lee KD, Lee CS, Jang HC, Kim HB, Lee HS et al. Production of C-reactive protein in Escherichia coli-infected patients with liver dysfunction due to liver cirrhosis. Diagn Microbiol Infect Dis 2005; 51: 227-230.
170. Lemmers A, Gustot T, Durnez A, Evrard S, Moreno C, Quertinmont E et al. An inhibitor of interleukin-6 trans-signalling, sgp130, contributes to impaired acute phase response in human chronic liver disease. Clin Exp Immunol 2009; 156: 518-527.
171. Thomsen KL, Hebbard L, Glavind E, Clouston A, Vilstrup H, George J et al. Non-alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats. Liver Int 2014; 34: 1584-1592.
172. Jepsen P, Vilstrup H, Mellemkjaer L, Thulstrup AM, Olsen JH, Baron JA et al. Prognosis of patients with a diagnosis of fatty liver-a registry-based cohort study. Hepato-gastroenterology 2003; 50: 2101-2104.
173. Dommett RM, Klein N, Turner MW. Mannose-binding lectin in innate immunity: past, present and future. Tissue Antigens 2006; 68: 193-209.
174. Keizer MP, Wouters D, Schlapbach LJ, Kuijpers TW. Restoration of MBL-deficiency: redefining the safety, efficacy and viability of MBLsubstitution therapy. Mol Immunol 2014; 61: 174-184.